Skip to main content
Log in

Cellular immunity for cancer chemoimmunotherapy—an overview

  • Symposium in Writing
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444–2448

    CAS  PubMed  Google Scholar 

  2. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockage in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712–4717

    Article  CAS  PubMed  Google Scholar 

  3. Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115–122

    CAS  PubMed  Google Scholar 

  4. Cao ZA, Daniel D, Hanahan D (2002) Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2:11

    Article  PubMed  Google Scholar 

  5. Ganss R, Limmer A, Sacher T, Arnold B, Hammerling GJ (1999) Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Immunol Rev 169:263–272

    CAS  PubMed  Google Scholar 

  6. Evans SS, Wang WC, Bain MD, Burd R, Ostberg JR, Repasky EA (2001) Fever-range hyperthermia dynamically regulates lymphocyte delivery to high endothelial venules. Blood 97:2727–2733

    Article  CAS  PubMed  Google Scholar 

  7. Mihich E, Ehrke MJ (1991) Immunomodulation by anticancer drugs. In: Devita V, Hillman S, S. Rosenberg S (eds) Biologic therapy of cancer: principles and practice. Part III. Alternative strategies for biologic therapy. Lippincott, Philadelphia, pp 776–786

    Google Scholar 

  8. Ehrke MJ, Mihich E (1996) Immunopharmacology of anticancer agents. In: Hadden JW, Szentivanyi A (eds) Immunopharmacology reviews, vol 2. Plenum, New York, pp 103–127

  9. Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES (2003) Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 52:463–472

    Google Scholar 

  10. Cowens JW, Ozer H, Ehrke MJ, Greco W, Colvin M, Mihich E (1984) Inhibition of the development of suppressor cells in culture by 4-Hydroperoxy-cyclophosphamide. J Immunol 132:95–100

    CAS  Google Scholar 

  11. Schiavoni G, Mattei F, Pucchio TD, Santini SM, Bracci L, Belardelli F, Proietti E (2000) Cyclophosphamide induced type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95:2024

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Enrico Mihich.

Additional information

This article forms part of the Symposium in Writing on "Cellular immunity for cancer chemoimmunotherapy" in Volume 52 (2003)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mihich, E. Cellular immunity for cancer chemoimmunotherapy—an overview. Cancer Immunol Immunother 52, 661–662 (2003). https://doi.org/10.1007/s00262-003-0423-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-003-0423-6

Keywords

Navigation